Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adefovir dipivoxil + polyene phosphatidylcholine
- Development stage
- Preclinical
- Lead developer
- Gilead Sciences
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Oral
01
Overview
Adefovir dipivoxil + polyene phosphatidylcholine is a combination therapy investigated primarily for the treatment of chronic hepatitis B. Adefovir dipivoxil is an oral prodrug of adefovir, an acyclic nucleotide analog of adenosine monophosphate. After conversion to its active metabolite, adefovir diphosphate, it inhibits hepatitis B virus (HBV) DNA polymerase (reverse transcriptase) by competing with deoxyadenosine triphosphate and causing DNA chain termination upon incorporation into viral DNA[6]. Polyene phosphatidylcholine (PPC) is used in China as a hepatoprotective agent for various liver diseases and drug-induced liver injury; it acts by stabilizing cell membranes and promoting hepatic regeneration[5]. The rationale for combining these agents is to enhance antiviral efficacy while potentially reducing hepatotoxicity associated with long-term antiviral therapy.
- Other names
- PPC
02
Targets
HBV Pol (Hepatitis B virus polymerase)POLG (Mitochondrial DNA polymerase gamma)POLA1 (DNA polymerase alpha)
Beyond the preview
Go deeper on adefovir dipivoxil + polyene phosphatidylcholine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adefovir dipivoxil + polyene phosphatidylcholine.